radspherin
oncoinvent
['radspherin ', 'rectal', 'colorectal', 'oncoinvent']
oncoinvent presents 15-month safety and efficacy data from ongoing rad-18-002 phase 1/2a trial of radspherin in colorectal cancer patients at the 2023 asco annual meeting 
Breaking news from Business Wire